This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (19)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ralf U. Peter, MD; Thomas Ruzicka, MD; Fritjof Eckert, MD
Department of Dermatology University of Munich Frauenlobstrasse 9-11 W-8000 Munich 2, Germany

Arch Dermatol. 1991;127(9):1420-1421.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Cyclosporine A is an immunosuppressive agent that has been used primarily in transplantation medicine. It has also been used in a variety of dermatologic diseases, including severe psoriasis vulgaris,¹ pyoderma gangrenosum,² granuloma anulare,³ vitiligo,⁴ Behçet's disease,⁵ pemphigus vulgaris,⁶ and alopecia areata.⁷ In lupus erythematosus, its use has met with limited success (unpublished observations).

Disabling morphea is a rare disease that is often resistant to most forms of treatment; intravenous administration of penicillin, steroids, and nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended.⁶

We describe two male patients, 50 and 40 years of age, respectively, who presented with severe, rapidly progressive disabling morphea, and who showed marked improvement on treatment with cyclosporine A, after treatment with NSAIDs, high-dose intravenous penicillin (both cases), diuretics, and high daily doses of methyl prednisolone (case 1 only) had been ineffective.

Report of Cases.—CASE 1.— . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?